News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement
News|Articles|December 30, 2024

Our Top 5 Social Media Posts of 2024

Author(s)Miranda Schmalfuhs

Check out our top five most engaged social media posts from the year 2024.

Advertisement

1.

2.

3.

4.

5.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement

Related Content

Advertisement
Stock.adobe.com

How FDA's Removal of the Two-Trial Requirement Affects Development Programs

ByNicholas Jacobus,Ron Lanton
March 10th 2026

AI has Redefined Healthcare Communication — and There’s No Opting Out

ByAlli Wiese
March 9th 2026
Stock.adobe.com

Pharmaceutical Executive Daily: Vinay Prasad Set to Leave CBER for Second Time

ByNicholas Jacobus
March 9th 2026
Stock.adobe.com

Novo Nordisk Signs Deal with Hims & Hers

ByMike Hollan
March 9th 2026
Stock.adobe.com

Ipsen Withdraws Tazverik from Market Due to Emerging Data from Clinical Trial

ByNicholas Jacobus
March 9th 2026
Advertisement
Advertisement

Trending on PharmExec

1

Vinay Prasad Out at CBER for Second Time in Under a Year

2

Ipsen Withdraws Tazverik from Market Due to Emerging Data from Clinical Trial

3

Mergers and Acquisitions Roundup: GSK and Alfasigma Enter Licensing Agreement for Linerixibat, Servier Enters $2.5 Billion Definitive Agreement to Acquire Day One Pharmaceuticals

4

Novo Nordisk Signs Deal with Hims & Hers

5

AI has Redefined Healthcare Communication — and There’s No Opting Out

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us